Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 3
2004 2
2005 2
2006 3
2007 12
2008 3
2009 3
2010 3
2011 6
2012 4
2013 10
2014 14
2015 16
2016 24
2017 30
2018 30
2019 19
2020 27
2021 28
2022 34
2023 28
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

258 results

Results by year

Filters applied: . Clear all
Page 1
Higher adalimumab concentration is associated with complete fistula healing in patients with perianal fistulizing Crohn's disease.
Papamichael K, Centritto A, Guillo L, Hier J, Sherman Z; International Consortium of Therapeutic drug Monitoring (spECTRUM); Cheifetz AS. Papamichael K, et al. Clin Gastroenterol Hepatol. 2024 Apr 29:S1542-3565(24)00397-5. doi: 10.1016/j.cgh.2024.04.005. Online ahead of print. Clin Gastroenterol Hepatol. 2024. PMID: 38692557 No abstract available.
Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn's disease and ulcerative colitis included in randomised controlled trials.
Peyrin-Biroulet L, Arkkila P, Armuzzi A, Danese S, Ferrante M, Jordi Guardiola, Jahnsen J, Louis E, Lukáš M, Reinisch W, Roblin X, Smith PJ, Kwon T, Kim J, Yoon S, Kim DH, Atreya R. Peyrin-Biroulet L, et al. Among authors: roblin x. BMC Gastroenterol. 2024 Mar 27;24(1):121. doi: 10.1186/s12876-024-03163-5. BMC Gastroenterol. 2024. PMID: 38539103 Free PMC article.
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial.
Danese S, Panaccione R, Feagan BG, Afzali A, Rubin DT, Sands BE, Reinisch W, Panés J, Sahoo A, Terry NA, Chan D, Han C, Frustaci ME, Yang Z, Sandborn WJ, Hisamatsu T, Andrews JM, D'Haens GR; GALAXI-1 Study Group. Danese S, et al. Lancet Gastroenterol Hepatol. 2024 Feb;9(2):133-146. doi: 10.1016/S2468-1253(23)00318-7. Epub 2023 Dec 14. Lancet Gastroenterol Hepatol. 2024. PMID: 38104569 Clinical Trial.
Adalimumab Drug Levels at Secondary Loss of Response Do Not Predict Response to Dose-intensification in Crohn's Disease: A Retrospective, International Multicenter Study.
Little RD, Swaine A, Reynolds R, Gibson DJ, Barrau M, D'Errico F, Hampal R, Sparrow MP, Roblin X, Irving PM, Ward MG. Little RD, et al. Among authors: roblin x. Inflamm Bowel Dis. 2023 Nov 10:izad248. doi: 10.1093/ibd/izad248. Online ahead of print. Inflamm Bowel Dis. 2023. PMID: 37951220
258 results